A new COVID-19 vaccine could soon be available to Americans this summer — and the familiar protein technology used to make it may make the vaccine more palatable to those who were wary of mRNA vaccines, experts believe.
On Tuesday, the Food and Drug Administration's (FDA) advisory committee will meet to review Novavax's submission for its vaccine, dubbed NVX-CoV2373. If endorsed by the committee, the FDA will likely authorize the shot for adults 18 and over. The move would mark the fourth vaccine to be approved for emergency use authorization in the United States.
